These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 9859160)

  • 1. [Statins (HMG-CoA reductase inhibitors), cholesterol and stroke].
    Marta-Moreno J; Echeandia C; Oliveros-Cid A; Figuerola A; Mola S
    Rev Neurol; 1998 Nov; 27(159):827-30. PubMed ID: 9859160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
    Richter WO; Jacob BG; Schwandt P
    Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HMG-CoA reductase inhibitors reduce stroke risk, total mortality.
    Am J Health Syst Pharm; 1997 Oct; 54(19):2152, 2154. PubMed ID: 9331434
    [No Abstract]   [Full Text] [Related]  

  • 5. "Statin" drugs, mortality, and stroke prevention.
    Stiffman MN
    J Fam Pract; 1997 Oct; 45(4):293-4. PubMed ID: 9379151
    [No Abstract]   [Full Text] [Related]  

  • 6. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
    Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
    Schuster H; Barter PJ; Stender S; Cheung RC; Bonnet J; Morrell JM; Watkins C; Kallend D; Raza A;
    Am Heart J; 2004 Apr; 147(4):705-13. PubMed ID: 15077101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
    Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A.
    Regazzi MB; Iacona I; Campana C; Gavazzi A; Viganò M; Perani G
    Transplant Proc; 1994 Oct; 26(5):2644-5. PubMed ID: 7940825
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of dyslipidemia of the elderly with simvastatin and pravastatin. Effectiveness and tolerance].
    Panuccio D; Trabatti MR; Romani A
    Clin Ter; 1994 May; 144(5):419-24. PubMed ID: 7924180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
    Strony J; Hoffman R; Hanson M; Veltri E
    Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy.
    Bottorff MB; Yenkowsky JP; Cave DG
    Clin Ther; 1999 Jan; 21(1):218-35. PubMed ID: 10090437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypercholesterolemia. The evidence supports use of statins.
    Aronow WS
    Geriatrics; 2003 Aug; 58(8):18-20, 26-8, 31-2. PubMed ID: 12938249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical evaluation of a selective inhibitor of cholesterol synthesis: pravastatin].
    Alessandri C; Peverini F
    Minerva Med; 1992 Nov; 83(11):677-93. PubMed ID: 1461539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin.
    Gotto AM
    Am J Cardiol; 2005 Sep; 96(5A):34F-38F. PubMed ID: 16126021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Primary and secondary prevention of coronary disease by statins].
    Ferrières J
    Ann Cardiol Angeiol (Paris); 1999 Feb; 48(2):128-36. PubMed ID: 12555337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The HMG-CoA reductase inhibitors simvastatin and pravastatin. No indication for side effects in use on humans].
    Schmidt J; Schmitt C; Hockwin O
    Fortschr Ophthalmol; 1991; 88(6):843-5. PubMed ID: 1794817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.